5 completed. 4 Phase 3, 1 Early Phase 1.
By phase and status
Follow Iron therapy: new trials by email Literature Review of Iron therapy trials Research Report on Iron therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Effect of Intravenous Iron Supplementation in Reducing Allogenic Blood Transfusion Iron Isomaltoside 1000, placebo - Complications Early Phase 1 Completed 80 2019-09-20 2020-01-22
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ) Daprodustat (GSK1278863), Placebo, Iron therapy - Anaemia Phase 3 Completed 614 2018-03-05 2024-04-02
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID) Daprodustat, Darbepoetin alfa, Iron therapy - Anaemia Phase 3 Completed 312 2017-05-11 2021-10-20
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) Daprodustat, rhEPO, Placebo - Anaemia, Aspergillosis, Allergic Bronchopulmonary Phase 3 Completed 2964 2016-09-28 2021-12-03
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) Daprodustat, Darbepoetin alfa, Placebo - Anaemia Phase 3 Completed 3872 2016-09-27 2024-04-02
Conditions studied Anemia (4) · Renal Insufficiency, Chronic (4) · Aspergillosis, Allergic Bronchopulmonary (1) · Kidney Failure, Chronic (1)
Sponsors GlaxoSmithKline (4) · Ain Shams University (1)
Countries Argentina (4) · Australia (4) · Canada (4) · Italy (4) · Mexico (4) · Poland (4) · Russia (4) · South Korea (4) · Spain (4) · United Kingdom (4) · United States (4) · Brazil (3) · France (3) · Germany (3) · India (3)
Top investigators Ayman Shoeb, professor (1)
Results publications PMID 36005278 , PMID 36565721 , PMID 38383961 , PMID 33744933 , PMID 34739194 , PMID 35377393 , PMID 36739866
NIH funding 2016 (3) , 2017 (1)